Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Predictive Oncology ( (POAI) ).
Predictive Oncology Inc., a Delaware corporation, announced on September 29, 2025, that it entered into securities purchase agreements with accredited investors for private placements involving cash and cryptocurrency offerings. The company plans to issue common stock and pre-funded warrants, with the proceeds primarily used to establish a cryptocurrency treasury strategy focusing on digital assets like Aethir tokens. This strategic move aims to enhance the company’s financial positioning and operational capabilities, while also initiating a digital asset treasury strategy to manage and acquire digital assets. Additionally, changes in the board of directors were announced, with Nancy Chung-Welch resigning and Shawn Matthews being appointed, reflecting the company’s strategic alignment with its new digital asset focus.
The most recent analyst rating on (POAI) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.
Spark’s Take on POAI Stock
According to Spark, TipRanks’ AI Analyst, POAI is a Neutral.
The overall stock score is primarily impacted by significant financial challenges, including declining revenues and negative profit margins. Technical analysis provides some hope for a rebound, but the bearish trend remains strong. Valuation metrics are poor, with a negative P/E ratio and no dividend yield.
To see Spark’s full report on POAI stock, click here.
More about Predictive Oncology
Average Trading Volume: 70,238
Technical Sentiment Signal: Strong Sell
Current Market Cap: $13.72M
For a thorough assessment of POAI stock, go to TipRanks’ Stock Analysis page.